Trials / Completed
CompletedNCT00192400
Trial to Assess the Safety and Tolerability of the Liquid Formulation of CAIV-T in Healthy Children.
A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Compare the Safety, Tolerability, Immunogenicity and Efficacy of One Dose and Two Doses of a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T) Compared With Placebo in Healthy Children
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 2,160 (planned)
- Sponsor
- MedImmune LLC · Industry
- Sex
- All
- Age
- 6 Months – 35 Months
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine the efficacy of the liquid formulation of CAIV-T against culture confirmed influenza illness in healthy children aged at least 6 months and less than 36 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CAIV-T |
Timeline
- Start date
- 2002-03-01
- Completion
- 2002-11-01
- First posted
- 2005-09-19
- Last updated
- 2006-10-03
Source: ClinicalTrials.gov record NCT00192400. Inclusion in this directory is not an endorsement.